Arthritis Research & Therapy

official impact factor 4.36

Open Access Highly Access

Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis

Annette HM van der Helm-van Mil*, Kirsten N Verpoort, Ferdinand C Breedveld, René EM Toes and Tom WJ Huizinga

Arthritis Research & Therapy 2005, 7:R949-R958 doi:10.1186/ar1767

Accesses  

  • Last 30 days: 48 accesses
  • Last year: 594 accesses
  • All time: 5836 accesses

Cited by

BioMed Central: 8 citations

Research article   Open Access Highly Accessed

Can anti-cyclic citrullinated peptide antibody-negative RA be subdivided into clinical subphenotypes?

Diederik PC De Rooy, Annemiek Willemze, Bart Mertens, Tom WJ Huizinga, Annette HM Van der Helm-van Mil Arthritis Research & Therapy 2011, 13:R180 (27 October 2011)

Research article   Open Access

Transforming growth factor β 869C/T and interleukin 6 -174G/C polymorphisms relate to the severity and progression of bone-erosive damage detected by ultrasound in rheumatoid arthritis

Fulvia Ceccarelli, Carlo Perricone, Martina Fabris, Cristiano Alessandri, Annamaria Iagnocco, Cinzia Fabro, Elena Pontarini, Salvatore De Vita, Guido Valesini Arthritis Research & Therapy 2011, 13:R111 (8 July 2011)

Review   Free

The use of citrullinated peptides and proteins for the diagnosis of rheumatoid arthritis

Ger JM Pruijn, Allan Wiik, Walther J van Venrooij Arthritis Research & Therapy 2010, 12:203 (15 February 2010)

Research article   Open Access Highly Accessed

Levels of anti-citrullinated protein antibodies and IgM rheumatoid factor are not associated with outcome in early arthritis patients: a cohort study

Jennie Ursum, Wouter H Bos, Nancy van Dillen, Ben AC Dijkmans, Dirkjan van Schaardenburg Arthritis Research & Therapy 2010, 12:R8 (12 January 2010)

Research article   Open Access Highly Accessed

Diagnostic and prognostic value of antibodies against chimeric fibrin/filaggrin citrullinated synthetic peptides in rheumatoid arthritis

Raimon Sanmartí, Eduard Graell, Maria L Perez, Guadalupe Ercilla, Odette Viñas, Jose A Gómez-Puerta, Jordi Gratacós, Alejandro Balsa, Maria J Gómara, Marta Larrosa, Juan D Cañete, Isabel Haro Arthritis Research & Therapy 2009, 11:R135 (2 September 2009)

Research article   Open Access

Differential responsiveness to immunoablative therapy in refractory rheumatoid arthritis is associated with level and avidity of anti-cyclic citrullinated protein autoantibodies: a case study

YK Onno Teng, Robert J Verburg, Kirsten N Verpoort, Gwendolyn MP Diepenhorst, Ingeborg M Bajema, Maarten JD van Tol, Els CM Jol-van der Zijde, Rene EM Toes, Tom WJ Huizinga, Jacob M van Laar Arthritis Research & Therapy 2007, 9:R106 (10 October 2007)

Research article   Open Access Highly Accessed

A case-control study of rheumatoid arthritis identifies an associated single nucleotide polymorphism in the NCF4 gene, supporting a role for the NADPH-oxidase complex in autoimmunity

Lina M Olsson, Anna-Karin Lindqvist, Henrik Källberg, Leonid Padyukov, Harald Burkhardt, Lars Alfredsson, Lars Klareskog, Rikard Holmdahl Arthritis Research & Therapy 2007, 9:R98 (26 September 2007)

Research article   Open Access Highly Accessed

Serial determination of cyclic citrullinated peptide autoantibodies predicted five-year radiological outcomes in a prospective cohort of patients with early rheumatoid arthritis

Olivier Meyer, Pascale Nicaise-Roland, Marie Santos, Colette Labarre, Maxime Dougados, Philippe Goupille, Alain Cantagrel, Jean Sibilia, Bernard Combe Arthritis Research & Therapy 2006, 8:R40 (26 January 2006)